Alpha Centric Advisors LLC Bluebird Bio, Inc. Transaction History

Alpha Centric Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 25, 2022	SELL	$8.96 - $16.31 $286,720 - $521,919	-32,000 Closed	0 $0
Q3 2021 Mar 09, 2022	SELL	$11.24 - $21.0 $11,240 - $21,000	-1,000 Reduced 3.03%	32,000 $612,000
Q2 2021 Mar 09, 2022	SELL	$18.04 - $22.09 $81,180 - $99,405	-4,500 Reduced 12.0%	33,000 $1.06 Million
Q1 2021 Mar 09, 2022	BUY	$16.59 - $33.89 $469,497 - $959,087	28,300 Added 307.61%	37,500 $1.13 Million
Q4 2020 Mar 11, 2022	BUY	$27.5 - $37.92 $253,000 - $348,864	9,200 New	9,200 $398,000
Q3 2020 Mar 11, 2022	SELL	$34.44 - $43.75 $5,166 - $6,562	-150 Closed	0 $0
Q2 2020 Mar 11, 2022	BUY	$27.12 - $45.97 $4,068 - $6,895	150 New	150 $9,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.